Profile of teriparatide in the management of postmenopausal osteoporosis
1Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA;
Abstract:
One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
Insights
Osteoporosis affects many postmenopausal women, increasing fracture risk. New anabolic agents like teriparatide build bone, offering a promising therapeutic approach for fracture prevention.
Area of Science:
- Endocrinology
- Bone Biology
- Geriatrics
Background:
- Osteoporosis is a significant health concern, with 50% of postmenopausal women at risk of fracture.
- Traditional therapies focus on inhibiting bone turnover.
- A new class of anabolic agents offers a paradigm shift by promoting new bone formation.
Purpose of the Study:
- To review the effectiveness, risks, timing, and clinical applications of teriparatide.
- To explore the role of anabolic agents in managing postmenopausal osteoporosis.
- To identify patient populations that may benefit most from teriparatide therapy.
Main Methods:
- Review of accumulating evidence on anabolic agents.
- Analysis of clinical data regarding teriparatide use.
- Synthesis of information on teriparatide's efficacy and safety profile.
Main Results:
- Teriparatide represents a new class of anabolic agents for osteoporosis.
- This therapy focuses on building new, stronger bone.
- Evidence is growing regarding optimal utilization and patient selection for teriparatide.
Conclusions:
- Teriparatide offers a novel approach to treating postmenopausal osteoporosis by stimulating bone formation.
- Understanding the specific benefits, risks, and appropriate timing is crucial for effective clinical use.
- Further research will continue to refine the application of teriparatide in managing osteoporosis.
Related Concept Videos
01:40Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
00:59The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...